CorMedix

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CorMedix and other ETFs, options, and stocks.

About CRMD

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. 

CEO
Joseph Todisco
CEOJoseph Todisco
Employees
65
Employees65
Headquarters
Berkeley Heights, New Jersey
HeadquartersBerkeley Heights, New Jersey
Founded
2006
Founded2006
Employees
65
Employees65

CRMD Key Statistics

Market cap
938.77M
Market cap938.77M
Price-Earnings ratio
5.58
Price-Earnings ratio5.58
Dividend yield
Dividend yield
Average volume
3.21M
Average volume3.21M
High today
$11.88
High today$11.88
Low today
$11.88
Low today$11.88
Open price
$11.57
Open price$11.57
Volume
374.00
Volume374.00
52 Week high
$17.43
52 Week high$17.43
52 Week low
$5.60
52 Week low$5.60

Stock Snapshot

As of today, CorMedix(CRMD) shares are valued at $11.88. The company's market cap stands at 938.77M, with a P/E ratio of 5.58.

On 2025-12-19, CorMedix(CRMD) stock traded between a low of $11.88 and a high of $11.88. Shares are currently priced at $11.88, which is 0.0% above the low and 0.0% below the high.

The CorMedix(CRMD)'s current trading volume is 374, compared to an average daily volume of 3.21M.

During the past year, CorMedix(CRMD) stock moved between $5.60 at its lowest and $17.43 at its peak.

During the past year, CorMedix(CRMD) stock moved between $5.60 at its lowest and $17.43 at its peak.

CRMD News

TipRanks 23h
CorMedix announces interim results for DefenCath

CorMedix (CRMD) Therapeutics announced interim results for the Company’s ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care’s...

Simply Wall St 1d
CorMedix: Reassessing Valuation After Strong Multi‑Year Share Price Performance

CorMedix (CRMD) has quietly delivered a strong year so far, and investors are starting to ask whether the recent share performance lines up with the company’s g...

CorMedix: Reassessing Valuation After Strong Multi‑Year Share Price Performance

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CRMD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.